Cerevel Therapeutics Holdings, Inc. – NASDAQ:CERE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Cerevel Therapeutics Holdings stock price monthly change
-1.80%
month
Cerevel Therapeutics Holdings stock price quarterly change
-4.41%
quarter
Cerevel Therapeutics Holdings stock price yearly change
+17.97%
year
Cerevel Therapeutics Holdings key metrics
Market Cap | 8.19B |
Enterprise value | 4.15B |
P/E | -11.2 |
EV/Sales | N/A |
EV/EBITDA | -12.28 |
Price/Sales | N/A |
Price/Book | 7.52 |
PEG ratio | 0.27 |
EPS | -2.73 |
Revenue | N/A |
EBITDA | -456.02M |
Income | -460.46M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCerevel Therapeutics Holdings stock price history
Cerevel Therapeutics Holdings stock forecast
Cerevel Therapeutics Holdings financial statements
| Jun 2023 | 0 | -99.53M | |
|---|---|---|---|
| Sep 2023 | 0 | -96.36M | |
| Dec 2023 | 8.24M | -132.66M | -1608.78% |
| Mar 2024 | 0 | -131.91M |
| Dec 2023 | 8.24M | -132.66M | -1608.78% |
|---|---|---|---|
| Mar 2024 | 0 | -131.91M | |
| Sep 2025 | 8.24M | -132.69M | -1609.23% |
| Oct 2025 | 0 | -138.02M |
Analysts Price target
Financials & Ratios estimates
| 2024-02-20 | -0.59 | -0.76 |
|---|---|---|
| 2024-03-20 | -0.58 | -0.59 |
| Jun 2023 | 894353000 | 543.85M | 60.81% |
|---|---|---|---|
| Sep 2023 | 821962000 | 549M | 66.79% |
| Dec 2023 | 1243298000 | 569.55M | 45.81% |
| Mar 2024 | 1127343000 | 562.88M | 49.93% |
| Jun 2023 | -77.32M | 61.75M | 37.61M |
|---|---|---|---|
| Sep 2023 | -72.63M | 51.39M | 1.19M |
| Dec 2023 | -97.42M | -150.20M | 508.37M |
| Mar 2024 | -119.66M | 19.16M | 4.47M |
Cerevel Therapeutics Holdings alternative data
| Aug 2023 | 319 |
|---|---|
| Sep 2023 | 322 |
| Oct 2023 | 322 |
| Nov 2023 | 322 |
| Dec 2023 | 321 |
| Jan 2024 | 321 |
| Feb 2024 | 321 |
| Mar 2024 | 334 |
| Apr 2024 | 334 |
| May 2024 | 334 |
| Jun 2024 | 355 |
| Jul 2024 | 355 |
Cerevel Therapeutics Holdings other data
87.49%
+3.60%
of CERE is owned by hedge funds
104
-1
129.74M
+5.59M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 105737 | 0 |
| Sep 2023 | 0 | 50000 |
| Oct 2023 | 17316964 | 0 |
| Nov 2023 | 0 | 180130 |
| Dec 2023 | 0 | 104465 |
| Jan 2024 | 0 | 50000 |
| Feb 2024 | 0 | 54667 |
| Mar 2024 | 0 | 50000 |
| Apr 2024 | 0 | 50000 |
| May 2024 | 0 | 50000 |
| Jun 2024 | 0 | 50000 |
| Jul 2024 | 0 | 25000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | COLES N ANTHONY director | Common Stock | 25,000 | $3.5 | $87,500 | ||
Sale | COLES N ANTHONY director | Common Stock | 25,000 | $41.18 | $1,029,525 | ||
Option | COLES N ANTHONY director | Stock Option (Right to Buy) | 25,000 | $3.5 | $87,500 | ||
Option | COLES N ANTHONY director | Stock Option (Right to Buy) | 50,000 | $3.5 | $175,000 | ||
Option | COLES N ANTHONY director | Common Stock | 50,000 | $3.5 | $175,000 | ||
Sale | COLES N ANTHONY director | Common Stock | 50,000 | $40.61 | $2,030,500 | ||
Option | COLES N ANTHONY director | Stock Option (Right to Buy) | 50,000 | $3.5 | $175,000 | ||
Option | COLES N ANTHONY director | Common Stock | 50,000 | $3.5 | $175,000 | ||
Sale | COLES N ANTHONY director | Common Stock | 50,000 | $42.1 | $2,105,150 | ||
Option | COLES N ANTHONY director | Stock Option (Right to Buy) | 50,000 | $3.5 | $175,000 |
| Quarter | Transcript |
|---|---|
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 7 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 22 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. N. Anthony Coles Jr., M.P.H. (1960) Chief Executive Officer & Executive Chairman | $1,240,000 |
| Dr. John J. Renger Ph.D. (1969) Chief Scientific Officer | $945,080 |
Ms. Kathleen Tregoning M.A. (1971) Chief Corporation Affairs Officer | $600,790 |
-
When is Cerevel Therapeutics Holdings's next earnings date?
Unfortunately, Cerevel Therapeutics Holdings's (CERE) next earnings date is currently unknown.
-
Does Cerevel Therapeutics Holdings pay dividends?
No, Cerevel Therapeutics Holdings does not pay dividends.
-
How much money does Cerevel Therapeutics Holdings make?
Cerevel Therapeutics Holdings has a market capitalization of 8.19B. Cerevel Therapeutics Holdings made a loss 432.84M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
-
What is Cerevel Therapeutics Holdings's stock symbol?
Cerevel Therapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CERE".
-
What is Cerevel Therapeutics Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cerevel Therapeutics Holdings?
Shares of Cerevel Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cerevel Therapeutics Holdings's key executives?
Cerevel Therapeutics Holdings's management team includes the following people:
- Dr. N. Anthony Coles Jr., M.P.H. Chief Executive Officer & Executive Chairman(age: 65, pay: $1,240,000)
- Dr. John J. Renger Ph.D. Chief Scientific Officer(age: 56, pay: $945,080)
- Ms. Kathleen Tregoning M.A. Chief Corporation Affairs Officer(age: 54, pay: $600,790)
-
How many employees does Cerevel Therapeutics Holdings have?
As Jul 2024, Cerevel Therapeutics Holdings employs 355 workers, which is 6% more then previous quarter.
-
When Cerevel Therapeutics Holdings went public?
Cerevel Therapeutics Holdings, Inc. is publicly traded company for more then 5 years since IPO on 30 Jul 2020.
-
What is Cerevel Therapeutics Holdings's official website?
The official website for Cerevel Therapeutics Holdings is cerevel.com.
-
Where are Cerevel Therapeutics Holdings's headquarters?
Cerevel Therapeutics Holdings is headquartered at 222 Jacobs Street, Cambridge, MA.
-
How can i contact Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings's mailing address is 222 Jacobs Street, Cambridge, MA and company can be reached via phone at +84 43042048.
Cerevel Therapeutics Holdings company profile:
Cerevel Therapeutics Holdings, Inc.
cerevel.comExchange:
NASDAQ
Full time employees:
355
Industry:
Biotechnology
Sector:
Healthcare
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
222 Jacobs Street
Cambridge, MA 02141
Cambridge, MA 02141
CIK: 0001805387
ISIN: US15678U1280
CUSIP: 15678U128
